Compare MCBS & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCBS | SLDB |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2019 | 2017 |
| Metric | MCBS | SLDB |
|---|---|---|
| Price | $36.17 | $8.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $33.00 | $16.36 |
| AVG Volume (30 Days) | 91.3K | ★ 2.6M |
| Earning Date | 04-24-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | 4.76 | ★ 34.97 |
| EPS | ★ 0.77 | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | $36.78 | N/A |
| Revenue Next Year | $2.44 | N/A |
| P/E Ratio | $47.03 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.53 | $3.79 |
| 52 Week High | $37.46 | $11.45 |
| Indicator | MCBS | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 54.97 | 41.82 |
| Support Level | $33.81 | $6.38 |
| Resistance Level | $37.46 | $8.87 |
| Average True Range (ATR) | 1.15 | 0.59 |
| MACD | -0.07 | -0.33 |
| Stochastic Oscillator | 49.84 | 5.18 |
MetroCity Bankshares Inc is a bank holding company. Through its banking subsidiary, it operates as a full-service commercial bank focused on delivering various financial products and services to the small-to medium-sized businesses and individuals in its markets, including many customers in diverse and multi-ethnic communities in metropolitan markets in the Eastern U.S., Texas and California. The company provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers, and a variety of other banking services. The majority of its revenue is generated in the form of interest income.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.